Outcome of Allogeneic Hematopoietic Stem Cell Transplantation

To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematopoietic Stem Cell Transplant (HSCT)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Medicine, Queen Mary Hospital, Hong Kong

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Exclusion criteria

participant who is unable to give informed consent in a prospective cohort.

Treatment and study plan

Primary outcomes

Overall survival

Time frame: 5 year

Time from HSCT to death or latest follow-up
Relapse-free survival

Time frame: 5 years

Time from HSCT to relapse, death or latest follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Harry HS Gill, MBBS, MD, FRCP, FRCPath

CONTACT

[email protected]

+852 22555859

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Official study title

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications

Important dates

Study start: 2024
Primary completion: 2029
Study completion: 2030
First posted: Nov 22, 2024
Registry last updated: Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting